Viral Blips During Suppressive Antiretroviral Treatment Are Associated with High Baseline HIV-1 RNA Levels

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2016 Jun 23

PMID 27329293

Citations 29

Authors

Erik Sorstedt

Staffan Nilsson

Anders Blaxhult

Magnus Gisslen

Leo Flamholc

Anders Sonnerborg

Aylin Yilmaz

Affiliations

Soon will be listed here.

Abstract

Background: Many HIV-1-infected patients on suppressive antiretroviral therapy (ART) have transiently elevated HIV RNA levels. The clinical significance of these viral blips is uncertain. We have determined the incidence of blips and investigated important associations in the Swedish HIV-cohort.

Methods: HIV-1-infected ART naïve adults who commenced ART 2007-2013 were retrospectively included. Viral blips were defined as a transient viral load between 50 and 500 copies/mL Subjects not suppressed after six months on ART were excluded.

Results: Viral blips were found in 76/735 included subjects (10.3 %) and in 90/4449 samples (2.0 %). Median blip viral load was 76 copies/mL (range 56-138). Median follow-up time was 170 weeks (range 97-240). Baseline viral load was higher in subjects with viral blips (median log10 4.85 copies/mL) compared with subjects without blips (median log10 4.55 copies/mL) (p < 0.01). There was a significant association between viral blips and risk for subsequent virological failure (p < 0.001).

Conclusions: The Swedish national HIV-cohort has a low incidence of viral blips (10 %). Blips were associated with high baseline viral load and an increased risk of subsequent virological failure.

Citing Articles

Identification of viral protein R of human immunodeficiency virus-1 (HIV) and interleukin-6 as risk factors for malignancies in HIV-infected individuals: A cohort study.

Matsunaga A, Ando N, Yamagata Y, Shimura M, Gatanaga H, Oka S PLoS One. 2024; 19(1):e0296502.

PMID: 38166062 PMC: 10760899. DOI: 10.1371/journal.pone.0296502.

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens.

Silva G, Mendicino C, Menezes de Padua C, Tupinambas U Einstein (Sao Paulo). 2023; 21:eAO0156.

PMID: 37255057 PMC: 10219625. DOI: 10.31744/einstein_journal/2023AO0156.

A Systematic Review and Meta-Analysis on the Impact of Statin Treatment in HIV Patients on Antiretroviral Therapy.

Mokgalaboni K, Phoswa W, Yates S, Lebelo S, Madiba S, Modjadji P Int J Environ Res Public Health. 2023; 20(9).

PMID: 37174188 PMC: 10177940. DOI: 10.3390/ijerph20095668.

Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.

Alvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem V Clin Infect Dis. 2023; 77(4):593-605.

PMID: 37052343 PMC: 10893964. DOI: 10.1093/cid/ciad219.

Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection.

Yuan D, Li M, Zhou Y, Shi L, Lu J, Fu G J Virus Erad. 2023; 9(1):100320.

PMID: 37008574 PMC: 10063406. DOI: 10.1016/j.jve.2023.100320.

References

Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View

Siliciano J, Kajdas J, Finzi D, Quinn T, Chadwick K, Margolick J . Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003; 9(6):727-8. DOI: 10.1038/nm880. View

Farmer A, Wang X, Ganesan A, Deiss R, Agan B, OBryan T . Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study. AIDS Res Ther. 2016; 13:16. PMC: 4802903. DOI: 10.1186/s12981-016-0100-4. View

Yukl S, Gianella S, Sinclair E, Epling L, Li Q, Duan L . Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010; 202(10):1553-61. PMC: 2997806. DOI: 10.1086/656722. View

Chun T, Nickle D, Justement J, Meyers J, Roby G, Hallahan C . Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008; 197(5):714-20. DOI: 10.1086/527324. View

Ruelle J, Debaisieux L, Vancutsem E, De Bel A, Delforge M, Pierard D . HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect Dis. 2012; 12:100. PMC: 3445837. DOI: 10.1186/1471-2334-12-100. View

Miller L, Golin C, Liu H, Hays R, Hua J, Wenger N . No evidence of an association between transient HIV viremia ("Blips") and lower adherence to the antiretroviral medication regimen. J Infect Dis. 2004; 189(8):1487-96. DOI: 10.1086/382895. View

Young J, Rickenbach M, Calmy A, Bernasconi E, Staehelin C, Schmid P . Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. BMC Infect Dis. 2015; 15:382. PMC: 4578247. DOI: 10.1186/s12879-015-1120-8. View

Fung I, Gambhir M, van Sighem A, de Wolf F, Garnett G . The clinical interpretation of viral blips in HIV patients receiving antiviral treatment: are we ready to infer poor adherence?. J Acquir Immune Defic Syndr. 2012; 60(1):5-11. DOI: 10.1097/QAI.0b013e3182487a20. View

10.

Sungkanuparph S, Overton E, Seyfried W, Groger R, Fraser V, Powderly W . Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis. 2005; 41(9):1326-32. DOI: 10.1086/496985. View

11.

Zoufaly A, Kiepe J, Hertling S, Hufner A, Degen O, Feldt T . Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals. HIV Med. 2014; 15(8):449-57. DOI: 10.1111/hiv.12134. View

12.

Jones L, Perelson A . Modeling the effects of vaccination on chronically infected HIV-positive patients. J Acquir Immune Defic Syndr. 2002; 31(4):369-77. DOI: 10.1097/00126334-200212010-00001. View

13.

Pomerantz R . Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials. 2003; 4(2):137-43. DOI: 10.1310/80jh-148k-nadq-u927. View

14.

Moore A, Youle M, Lipman M, Cozzi-Lepri A, Lampe F, Madge S . Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?. AIDS. 2002; 16(4):615-8. DOI: 10.1097/00002030-200203080-00013. View

15.

Maldarelli F, Palmer S, King M, Wiegand A, Polis M, Mican J . ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007; 3(4):e46. PMC: 1847689. DOI: 10.1371/journal.ppat.0030046. View

16.

Rizzardi G, de Boer R, Hoover S, Tambussi G, Chapuis A, Halkic N . Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest. 2000; 105(6):777-82. PMC: 377467. DOI: 10.1172/JCI9079. View

17.

Podsadecki T, Vrijens B, Tousset E, Rode R, Hanna G . Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis. 2008; 196(12):1773-8. DOI: 10.1086/523704. View

18.

Sizmann D, Glaubitz J, Simon C, Goedel S, Buergisser P, Drogan D . Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach. J Clin Virol. 2010; 49(1):41-6. DOI: 10.1016/j.jcv.2010.06.004. View

19.

Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C . Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5. DOI: 10.1126/science.278.5341.1291. View

20.

Kanapathipillai R, McManus H, Kamarulzaman A, Lim P, Templeton D, Law M . The significance of HIV 'blips' in resource-limited settings: is it the same? analysis of the treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD). PLoS One. 2014; 9(2):e86122. PMC: 3917848. DOI: 10.1371/journal.pone.0086122. View